Compare GREE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GREE | INTS |
|---|---|---|
| Founded | 1937 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | GREE | INTS |
|---|---|---|
| Price | $1.38 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 172.1K | ★ 1.3M |
| Earning Date | 03-31-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,115,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $0.19 |
| 52 Week High | $2.42 | $2.56 |
| Indicator | GREE | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 44.17 |
| Support Level | $1.30 | $0.37 |
| Resistance Level | $1.48 | $0.42 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 13.95 | 31.21 |
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center. Company operates in three segments: Crypto Mining, Datacenter Hosting, Power and Capacity. The company owns and operates facilities at two locations: the Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.